KoBioLabs, Inc (KOSDAQ:348150)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,605.00
+30.00 (0.66%)
Last updated: Mar 25, 2025
-46.82%
Market Cap 83.02B
Revenue (ttm) 61.29B
Net Income (ttm) -9.47B
Shares Out 19.37M
EPS (ttm) -497.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,907
Average Volume 27,637
Open 4,590.00
Previous Close 4,575.00
Day's Range 4,520.00 - 4,625.00
52-Week Range 4,520.00 - 9,210.00
Beta 0.68
RSI 22.72
Earnings Date Mar 21, 2025

About KoBioLabs

KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and neurological diseases. The company is based in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO GwangPyo Ko
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 348150
Full Company Profile

Financial Performance

In 2023, KoBioLabs's revenue was 33.14 billion, an increase of 185.54% compared to the previous year's 11.61 billion. Losses were -13.85 billion, -36.81% less than in 2022.

Financial Statements

News

There is no news available yet.